Astrocytomas of the spinal cord
- PMID: 39430394
- PMCID: PMC11485950
- DOI: 10.1093/noajnl/vdad166
Astrocytomas of the spinal cord
Abstract
Tumors of astrocytic origin represent one of the most frequent entities among the overall rare group of spinal cord gliomas. Initial clinical symptoms are often unspecific, and sensorimotor signs localizing to the spinal cord occur with progressing tumor growth. On MRI, a hyperintense intrinsic spinal cord signal on T2-weighted sequences with varying degrees of contrast enhancement raises suspicion for an infiltrative neoplasm. Blood and CSF analysis serves to exclude an infectious process, nutritional deficits, or metabolic disorders. When such other differential diagnoses have been ruled out, a neuropathological tissue-based analysis is warranted to confirm the diagnosis of a spinal cord astrocytoma and guide further patient management. As such, maximal safe resection forms the basis of any treatment. Meticulous preoperative planning is necessary to weigh the potential improvement in survival against the risk of functional deterioration. Intraoperative neuromonitoring and ultrasound may aid in achieving a more extensive resection. Depending on the assigned WHO tumor grade spanning from grade 1 to grade 4, the use of radiotherapy and chemotherapy might be indicated but also wait-and-scan approaches appear reasonable in tumors of lower grade. Close imaging follow-up is necessary given that recurrence inevitably occurs in astrocytomas of grades 2-4. Prognosis is so far dictated by tumor grade and histopathological findings, but also by age and clinical performance of the patient. Targeted therapies resting upon an in-depth tissue analysis are emerging in recurrent tumors, but no prospective study is available so far given the rarity of spinal cord astrocytomas.
Keywords: astrocytoma; glioma; outcome; spinal cord; surgery; therapy.
© The Author(s) 2024. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
Conflict of interest statement
None declared.
Figures
Similar articles
-
Primary Spinal Astrocytomas: A Literature Review.Cureus. 2019 Jul 26;11(7):e5247. doi: 10.7759/cureus.5247. Cureus. 2019. PMID: 31565645 Free PMC article. Review.
-
Intramedullary spinal cord ependymoma and astrocytoma: intraoperative frozen-section diagnosis, extent of resection, and outcomes.J Neurosurg Spine. 2018 Oct 19;30(1):133-139. doi: 10.3171/2018.7.SPINE18230. Print 2019 Jan 1. J Neurosurg Spine. 2018. PMID: 30485241
-
Clinicopathological characteristics and survival of spinal cord astrocytomas.Cancer Med. 2020 Oct;9(19):6996-7006. doi: 10.1002/cam4.3364. Epub 2020 Aug 10. Cancer Med. 2020. PMID: 32777166 Free PMC article.
-
The Role of Radiotherapy, Chemotherapy, and Targeted Therapies in Adult Intramedullary Spinal Cord Tumors.Cancers (Basel). 2024 Aug 6;16(16):2781. doi: 10.3390/cancers16162781. Cancers (Basel). 2024. PMID: 39199553 Free PMC article. Review.
-
The role of radiotherapy in the management of spinal cord glioma.Int J Radiat Oncol Biol Phys. 1995 Sep 30;33(2):323-8. doi: 10.1016/0360-3016(95)00179-3. Int J Radiat Oncol Biol Phys. 1995. PMID: 7673019
Cited by
-
Evolution of glioma exosome research: emerging trends and global collaborations (2005-2025).Discov Oncol. 2025 Jul 16;16(1):1345. doi: 10.1007/s12672-025-03167-x. Discov Oncol. 2025. PMID: 40668464 Free PMC article.
References
-
- Luksik AS, Garzon-Muvdi T, Yang W, Huang J, Jallo GI.. Pediatric spinal cord astrocytomas: a retrospective study of 348 patients from the SEER database. J Neurosurg Pediatr. 2017;19(6):711–719. - PubMed
-
- Jallo GI, Freed D, Epstein F.. Intramedullary spinal cord tumors in children. Childs Nerv Syst. 2003;19(9):641–649. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials